Treatment of Latent Tuberculosis Infection : Maximizing Adherence

Details

• Corporate Authors:
  National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination.
• Description:
  Latent tuberculosis infection (LTBI) is the presence of M. tuberculosis organisms (tubercle bacilli) without symptoms or radiographic or bacteriologic evidence of TB disease. Approximately 90-95% of those infected are able to mount an immune response that halts the progression from LTBI to TB disease. However, because prevention of TB has major public health implications, the Centers for Disease Control and Prevention (CDC) and the United States Preventive Services Task Force (USPSTF) recommend testing populations that are at increased risk for TB infection and treating those for whom TB disease has been ruled out. Health care providers must communicate the risks and benefits of treatment to their patients and encourage adherence and treatment completion.
  
  CS227840_E
  
  adherence_revised.pdf
  
  
• Subjects:
  Latent Tuberculosis Tuberculosis/drug Therapy Tuberculosis/prevention & Control Tuberculosis/transmission
• Series:
  TB Elimination
• Document Type:
  Text
• Genre:
  Fact Sheet
• Pages in Document:
  2 numbered pages
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha-512:950cffb2ba275769fb474d4220e04382eb226ad3870d83a8677a7f538a56dff2409def40a00289dd6a5f00705863d0d04c137741eb4e8ab5d1afab9a76e8f359
• Download URL:
  https://stacks.cdc.gov/view/cdc/132168/cdc_132168_DS1.pdf
• File Type:
  [PDF - 672.25 KB ]